GCP
OGEN icon

GSA Capital Partners’s Oragenics OGEN Stock Holding History

GSA Capital Partners’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-228
Closed -$183K – 1710
2021
Q4 		$183K Buy
228
+137
+151% +$139K 0.02% 1244
2021
Q3 		$104K Buy
+91
New +$110K 0.01% 1320
2021
Q2 		– Sell
-27
Closed -$44K – 1518
2021
Q1 		$44K Sell
27
-30
-53% -$54.5K 0.01% 1033
2020
Q4 		$46K Buy
57
+28
+97% +$24.6K 0.01% 1138
2020
Q3 		$30K Buy
+29
New +$46.3K 0.01% 1207

Other funds holding OGEN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SBF
Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GSA Capital Partners's OGEN Position: Q1 2022 in Review

GSA Capital Partners sold out of Oragenics (OGEN) in Q1 2022, closing a stake of 228 shares — an estimated $183K sold.

GSA Capital Partners first reported a position in OGEN in Q3 2020 and held it in 5 quarters. The position peaked at $183K in Q4 2021. 24 funds tracked by Wall St. Rank hold OGEN as of Q1 2022.

  • GSA Capital Partners reported no remaining Oragenics position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 228 Oragenics shares in Q1 2022, an estimated $183K.
  • GSA Capital Partners first reported a position in Oragenics in Q3 2020 and held it in 5 quarters.
  • GSA Capital Partners's Oragenics position peaked at $183K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Oragenics as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.